BEHANDLUNG VON REFRAKTÄRER MIGRÄNE

Patent europeic · EP3515937 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3515937
Numer da la dumonda
EP17785013
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
22-09-2017
Publitgà
31-07-2019
Concedì
17-12-2025
La protecziun finescha il pli tard
21-09-2037
Proxima taxa annuala scadenta
30-09-2027
Classas IPC
C07K 16/18 (2006.01)
A61P 25/06 (2006.01)
A61K 39/00 (2006.01)
Prioritad
US 201662399180 P 23.09.2016
US 201762558557 P 14.09.2017
Dumonda PCT
PCT/IB2017/055777 22.09.2017
Publicaziun PCT
WO2018/055574 29.03.2018
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-10-2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  2. 14-01-2026

    Represchentant inscrit

    Representative
    E. Blum & Co. AG, Hofwiesenstrasse 349, 8050 Zürich

    Published in Swissreg on 14.01.2026

  3. 17-12-2025

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 17.12.2025

Partidas

Possessur

Teva Pharmaceuticals International GmbH

Schlüsselstrasse 12, 8645 Rapperswil-Jona

Represchentant

E. Blum & Co. AG

Hofwiesenstrasse 349, 8050 Zürich

Inventur

BIGAL, Marcelo

Doylestown Pennsylvania 18902, US

AYCARDI, Ernesto

Andover Massachusetts 10810, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.